MedTrace Logo

Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment

NCT05225155 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2022-09-10

No results posted yet for this study

Summary

Retrospective study designed to evaluate outcomes in patients undergoing assisted reproduction. Some of them had thrombophilia, and part of them was treated with enoxaparin, started on the day of embryo transfer, and the other part not. Women without thrombophilia formed the control group.

Conditions

  • Infertility, Female
  • Thrombophilia
  • Fertilization in Vitro

Interventions

DRUG

Enoxaparin

Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation

Sponsors & Collaborators

  • Faculdade de Medicina do ABC

    lead OTHER

Principal Investigators

  • Luciano M Pompei · Faculdade de Medicina do ABC

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-02
Primary Completion
2015-11-30
Completion
2019-08-31
FDA Drug
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225155 on ClinicalTrials.gov